ICO Guidance on Lawful Basis for Personal Data Processing

The UK's Information Commissioner's Office (ICO) has updated its guidance on the lawful basis for processing personal data. This guidance is under review due to upcoming legislation, the Data (Use and Access) Act 2025, and may be subject to change.

UK GDPR: Controllers and Processors Definitions and Responsibilities

The UK's Information Commissioner's Office (ICO) has updated its guidance on definitions and responsibilities for data controllers and processors under UK GDPR. This update is in anticipation of the Data (Use and Access) Act 2025 and is suitable for large businesses, with resources also available for small businesses.

ICO Guidance on UK GDPR International Data Transfers

The UK's Information Commissioner's Office (ICO) has published updated guidance on international transfers of personal data under UK GDPR. The guidance consolidates information on adequacy regulations, appropriate safeguards, transfer risk assessments, and exceptions for restricted transfers.

MHRA Medical Devices Exceptional Use Authorisations List Updated

The UK's MHRA has updated its list of medical devices granted exceptional use authorisations. This guidance document provides transparency on manufacturers and devices that have received exemptions, including those whose authorisations have expired or been cancelled.

MHRA: Stop using non-sterile alcohol-free wipes due to infection risk

The MHRA and UKHSA are advising the public not to use four specific non-sterile alcohol-free wipe products due to contamination with Burkholderia stabilis bacteria. These products have been withdrawn from sale, but may still be in homes, and are linked to 59 cases, including one death.

MHRA: Quetiapine Oral Suspension Recalled Due to Incorrect Active Ingredient

The MHRA has issued a recall for all batches of quetiapine oral suspension manufactured by Eaststone Limited due to an incorrect amount of the active ingredient, potentially leading to overdose. Approximately 166 bottles manufactured between October 2025 and January 2026 are affected. Patients are advised not to stop medication without consulting a healthcare professional.

MHRA Updates GLP-1 Guidance on Pancreatitis Risk

The MHRA has updated product information regarding the small risk of severe acute pancreatitis associated with GLP-1 medications. Healthcare professionals and patients are reminded to be alert to symptoms, and the MHRA is investigating genetic factors influencing this risk.

MHRA Updates Semaglutide Guidance on NAION Risk

The MHRA has updated its guidance for semaglutide prescribers and patients regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION). The update alerts healthcare professionals and patients to the symptoms and advises immediate medical attention if vision changes occur. This guidance follows three reports of NAION associated with semaglutide since 2018.

FTC Sending $22.8 Million to Consumers for Deceptive Real Estate Schemes

The FTC is returning nearly $23 million to 1,659 consumers who were defrauded by deceptive real estate schemes, specifically Sanctuary Belize and Kanantik. This second distribution includes checks averaging $16,462 for Sanctuary Belize investors and $6,346.39 for Kanantik investors.

FTC Settlement with Express Scripts to Lower Drug Costs

The FTC has secured a settlement with Express Scripts, Inc. (ESI), a major pharmacy benefit manager, requiring significant changes to its business practices. These changes are projected to lower drug costs for patients by up to $7 billion over 10 years and increase revenue for community pharmacies.